Worldwide BiotechBiopharma Alliance within the Two Days
On Nov. 14, 2013, MRC Technology announced that it is collaborating with Dr Zameel Cader at Oxford University’s Nuffield Department of Clinical Neurosciences, to screen selective and potent potassium channel activators to develop novel therapeutic interventions in migraine.
On Nov. 13, 2013, Vitrolife AB announced to increase their collaboration on stem cells after the earlier collaboration with the Stockholm-based Biolamina AB within the stem-cell field since 2012.
On Nov. 13, 2013, Immatics and Roche announced a strategic research and development collaboration covering multiple cancer vaccines and immunotherapeutics. The agreement will focus on the research, clinical development and commercialisation of a number of new tumour-associated peptide (TUMAP)-based cancer vaccine candidates and other immunotherapies in oncology, targeting primarily gastric, prostate and non-small cell lung cancer.
On Nov. 13, 2013, ImmunoGen, Inc. announced that Novartis has licensed the exclusive right to use the Company's antibody-drug conjugate (ADC) technology to develop anticancer therapeutics to an undisclosed target. This is the third license to be taken by Novartis – and the fifth to be taken by a major healthcare company – this year.
On Nov. 13, 2013, Merck announced that a global licensing, co-development, and commercialization agreement for BeiGene-290 has been signed with BeiGene Co., Ltd. The compound, which is a potent poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of cancer, is currently in preclinical development and is expected to enter clinical development next year. This is the second collaboration agreement between the two companies this year.
Article Link: Worldwide BiotechBiopharma Alliance within the Two Days